[institut] Lecture Announcement: PBPK Modeling – Dr. Jasmina Novaković, August 26

[Darija Obradović]

Dear colleagues,

I am pleased to invite you to a lecture by Dr. Jasmina Novaković 
entitled:

PBPK Modeling: Principles and Applications in Drug Development

Wednesday, August 26, 2026
12:00–13:00
Dr. Dragan Popović Lecture Hall, Institute of Physics Belgrade

Speaker Biography

Dr. Jasmina Novaković is a pharmaceutical scientist currently working in 
Canada as a Senior PBPK Consultant at Certara, Simcyp Division. She has 
more than two decades of international experience in drug development, 
research, education, and scientific consulting, with a particular focus 
on computational modeling and simulation within the framework of 
Model-Informed Drug Development (MIDD) and physiologically based 
pharmacokinetic (PBPK) modeling.

Prior to joining Certara, she was Principal Scientist for PBPK Modeling 
at Simulations Plus (2019–2025) and held a scientific leadership 
position in research and development at Apotex in Toronto (2007–2019). 
She also conducted research in preclinical drug development at the 
University of Toronto and taught clinical pharmacology at Seneca 
Polytechnic in Toronto. Earlier in her career, she worked in 
pharmaceutical research in Prague and at the Faculty of Pharmacy, 
University of Belgrade.

Dr. Novaković is active in the international pharmaceutical science 
community and has been an invited speaker at numerous scientific 
conferences, workshops, and professional meetings. She has served on the 
United States Pharmacopeia (USP) Expert Group for Small Molecules since 
2015 and has been a member of the Board of Directors of the Canadian 
Society for Pharmaceutical Scientists (CSPS) since 2025.

Lecture Abstract

In this lecture, Dr. Novaković will introduce the fundamental principles 
of physiologically based pharmacokinetic (PBPK) modeling and discuss its 
applications in modern drug development.

PBPK models integrate information about the physicochemical and 
pharmacokinetic properties of biologically active molecules with 
mathematical descriptions of human physiology to simulate and predict 
drug absorption, distribution, metabolism, and elimination.

This approach is closely related to the emerging concept of digital 
twins in biomedicine. By creating computational representations of 
biological systems, simulations can be used to explore and predict how 
biologically active molecules behave in the human body under different 
physiological conditions, including variability between individuals and 
populations. Such in silico approaches can complement experimental and 
clinical studies and increasingly contribute to decision-making 
throughout the drug-development process.

The lecture will provide an opportunity to learn about a rapidly 
developing field at the intersection of physics, computational modeling, 
mathematics, biology, pharmacology, and medicine, and to discuss how 
computational simulations and digital-twin approaches can contribute to 
predicting the behavior of biologically active molecules.

I hope you will be able to join us.

Best regards,
Dr. Darija Obradović
Biomimetics Laboratory